Trial reportThe Journal of clinical endocrinology and metabolism2012
Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study.
Trial report in The Journal of clinical endocrinology and metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Bone and mineral metabolism in patients with primary aldosteronism: A systematic review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Vitamin D supplementation for cardiometabolic risk markers in pregnant women based on the gestational diabetes mellitus or obesity status : a randomized clinical trial.European journal of nutrition · 2024Trial
- Effect of vitamin D3 supplementation on vascular and metabolic health of vitamin D-deficient overweight and obese children: a randomized clinical trial.The American journal of clinical nutrition · 2020Trial
- The effect of vitamin D on renin-angiotensin system activation and blood pressure: a randomized control trial.Journal of hypertension · 2017Trial
- Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.Journal of the American Society of Nephrology : JASN · 2017Trial
- The VITAH trial VITamin D supplementation and cardiac Autonomic tone in Hemodialysis: a blinded, randomized controlled trial.BMC nephrology · 2014Trial
- Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone.Hypertension (Dallas, Tex. : 1979) · 2014Trial
- A randomized intervention study to evaluate the effect of calcitriol therapy on the renin-angiotensin system in diabetes.Journal of the renin-angiotensin-aldosterone system : JRAASTrial
- Subclinical Primary Aldosteronism Is Characterized by Maladaptive Natriuretic Peptide and Adrenal Hormonal Physiology.The Journal of clinical endocrinology and metabolism · 2025Observational
- Vitamin D and Cardiovascular Disease: The "Good", the "Bad", and the "Unknown".Reviews in cardiovascular medicine · 2025Review
- Vitamin - D deficiency as a risk factor in primary hypertension - A cross sectional study.Bioinformation · 2025Article
- Adverse pregnancy outcomes and renal-vascular function in the early years after delivery.American journal of physiology. Heart and circulatory physiology · 2024Article
- Latest Knowledge on the Role of Vitamin D in Hypertension.International journal of molecular sciences · 2023Review
- Fok I and Bsm I gene polymorphism of vitamin D receptor and essential hypertension: a mechanistic link.Clinical hypertension · 2023Review
- Article
- Interaction of Vitamin D with Peptide Hormones with Emphasis on Parathyroid Hormone, FGF23, and the Renin-Angiotensin-Aldosterone System.Nutrients · 2022Review
- Obesity-Associated Vitamin D Deficiency Correlates with Adipose Tissue DNA Hypomethylation, Inflammation, and Vascular Dysfunction.International journal of molecular sciences · 2022Article
- Vitamin D Deficiency Is a Potential Risk for Blood Pressure Elevation and the Development of Hypertension.Medicina (Kaunas, Lithuania) · 2021Article
- Vitamin D and cardiovascular health.Clinical nutrition (Edinburgh, Scotland) · 2021Review
- A clinical trial to evaluate the effect of statin use on lowering aldosterone levels.BMC endocrine disorders · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
contextVitamin D deficiency and obesity are associated with increased tissue renin-angiotensin system (RAS) activity.
objectiveThe objective of the study was to evaluate whether vitamin D(3) therapy in obesity reduces tissue-RAS activity, as indicated by an increase in tissue sensitivity to angiotensin II (AngII).
participantsParticipants included obese subjects with hypertension and 25-hydroxyvitamin D less than 25 ng/ml.
designSubjects were studied before and after 1 month of vitamin D(3) 15,000 IU/d, while in dietary sodium balance, and off all interfering medications. Fourteen subjects successfully completed all study procedures.
settingThe study was conducted at a clinical research center. OUTCOME MEASURES: At each study visit, tissue sensitivity to AngII was assessed by measuring renal plasma flow (RPF), mean arterial pressure (MAP), and adrenal secretion of aldosterone during an infusion of AngII. Subjects were then given captopril, and a second AngII infusion to evaluate the effect of captopril on tissue-RAS activity.
resultsVitamin D(3) therapy increased 25-hydroxyvitamin D (18 to 52 ng/ml) and basal RPF (+5%) and lowered supine MAP (-3%) (all P < 0.01). There was a greater decline in RPF and higher stimulation of aldosterone with AngII infusion after vitamin D(3) therapy (both P < 0.05). As anticipated, captopril increased the renal-vascular, MAP, and adrenal sensitivity to AngII, but this effect was much smaller after vitamin D(3) therapy, indicating that vitamin D(3) therapy corrected the tissue sensitivity to AngII akin to captopril.
conclusionsVitamin D(3) therapy in obese hypertensives modified RPF, MAP, and tissue sensitivity to AngII similar to converting enzyme inhibition. Whether chronic vitamin D(3) therapy abrogates the development of diseases associated with excess RAS activity warrants investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.